



Intestinal microsporidiosis in Iran: infection in immune-compromised and immunocompetent patients

Nooshadokht M^{1,6}, Sharifi I², Mohammadi MA³, Pirestani M⁴, Afgar A³, Mahootchi A¹, Salari S⁵, Babaei Z^{2*}

¹ Department of Medical Parasitology and Mycology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

² Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran

³ Research Center for Hydatid Disease in Iran, Kerman University of Medical Sciences, Kerman, Iran

⁴ Department of Parasitology and Entomology, School of Medicine, Tarbiat Modares University, Tehran, Iran

⁵ Regional Knowledge Hub and WHO Collaborating Centre for HIV Surveillance, Kerman University of Medical Sciences, Kerman, Iran

⁶ Department of Pathobiology, School of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran

Article Info

Article type:

Original article

Article History:

Received: 29 July 2017

Revised: 17 October 2017

Accepted: 11 November 2017

* Corresponding author:

Zahra Babaei

Leishmaniasis Research Center,
Kerman University of Medical
Sciences, Kerman, Iran.

Email: Zbabaei@kmu.ac.ir

ABSTRACT

Background and Purpose: Gastroenteritis and the clinical profile caused by *Microsporidia*, an opportunistic pathogen, may be severe in immunocompromised individuals, especially in AIDS patients. Conventionally, it is necessary to detect the small infective spores in stained smears. However, due to the limitations of the microscopy-based methods, several DNA-based methods such as polymerase chain reaction (PCR) have recently been developed to enhance diagnosis sensitivity. Therefore, we sought to evaluate the rate of infection in immunocompromised patients as compared with immunocompetent patients in Kerman, Iran.

Materials and Methods: We collected stool samples of 199 human subjects (116 males and 83 females), aged 1 to 69 years old. They were divided into immunocompromised (i.e., AIDS [n=72] and cancer-positive patients [n=59]) and immunocompetent (n=68) groups. We comparatively examined the fecal materials using the microscopy and PCR methods.

Results: The overall prevalence rate of *Microsporidia* infection was 10.05% (20/199). *Enterocytozoon bienewsi* was the only species within the *Microsporidia* genus that was identified in 14.5% (19/131) of the immunocompromised patients and 1.47% (1/68) of the immunocompetent individuals.

Conclusion: Considering the higher prevalence rate of microsporidiosis in patients with immunodeficiency (10.03%), we suggest performing sensitive and specific techniques such as PCR for the detection of these parasites in immunocompromised patients.

Keywords: Immunocompetent individuals, Immunocompromised patients, Iran, *Microsporidia*

► How to cite this paper

Nooshadokht M, Sharifi I, Mohammadi MA, Pirestani M, Afgar A, Mahootchi A, Salari S, Babaei Z. Intestinal microsporidiosis in Iran: infection in immunocompromised and immunocompetent patients. *Curr Med Mycol.* 2017; 3(1): 30-36. DOI: 10.29252/cmm.3.1.30

Introduction

Microsporidia is an intracellular eukaryotic microorganism that infects numerous animal and human cells [1]. Consistent with the results of recent phylogenetic and genetic analyses, the hypothesis that *Microsporidia* may be real fungi has been supported. It seems that this species has a very special evolutionary relationship with zygomycetes [2, 3].

Two species of *Microsporidia*, including *Enterocytozoon bienewsi* and *Encephalitozoon intestinalis*, are the most common etiological agents of intestinal infection in humans [4]. Immunocompromised, especially AIDS, patients with CD4⁺ T cell count of less than 100 / μ l are at high risk for this type of infection. In this group of patients, the infection can

be life-threatening [4, 5].

The course of infection and its response to treatment is generally different in immunocompetent individuals in comparison with AIDS patients. Besides, the former group is able to control the infection even without treatment [6, 7]. Other than AIDS, immunodeficiency disorders such as neoplastic diseases are the risk factors for the development of severe forms of microsporidiosis.

There is a necessity for the use of more sensitive diagnostic tests than microscopy because microscopic examination has some limitations in detecting very small *Microsporidia* spores [8].

In the past decade, the staining and molecular-based methods for identifying the microorganism have

improved exponentially [6, 9]. In the present study, the prevalence of intestinal microsporidiosis in immune-compromised and immunocompetent patients was examined using different protocols, in Kerman, Iran.

Materials and Methods

This cross-sectional study was performed at Kerman University of Medical Sciences, Kerman, Iran. The participants were classified into three groups of cancer patients (n=59), HIV-positive patients (n=72) visiting hospitals for follow-up examination and treatment, and immunocompetent patients with diarrhea as the control group (n=68). Three stool specimens were collected from each of the 199 participants.

The study was approved by the Ethics Committee (IR.KMU.REC.1394.325) of Kerman University of Medical Sciences.

Stool specimens and processing

Stool samples were immediately transported to the parasitology laboratory and divided into several portions according to the type of examination.

Ryan Blue modified trichrome staining method

First, two smears were prepared from 10 µl of fresh or concentrated stool samples on glass slides followed by spreading an area measuring about 25×45 mm. The air-dried smears were fixed with absolute methanol for 5 min, placed in the trichrome stain for 90 min, and then rinsed in alcohol-acid (1% glacial acetic acid in 96% ethanol) for 10 s. The samples were rinsed several times with 95% ethanol followed by dehydration with 95% and absolute ethanol for 5 and 10 min, respectively. The smears were placed in xylene for 10 min, and finally, they were mounted and covered with coverslips in the last step [10].

Genomic DNA extraction

Microsporidian spore walls were mechanically disrupted using glass beads (0.45-0.52 mm in diameter), and lysed by vortexing and freezing and thawing. After addition of 25 µl of proteinase K, the suspension was incubated at 56°C for 4-6 h followed by using QIAamp DNA stool mini kit (Qiagen Company, Germany) for DNA extraction as described by the manufacturer's instructions. The concentration and purity of the extracted DNA were measured with optical density (OD) ratio at 260/280 nm by using a NanoDrop spectrophotometer (Thermo Fisher Scientific). All the extracted DNAs were stored at -20°C.

PCR for the detection of *Microsporidia*

Four primers were used for *E. bienewisi* and *E. intestinalis* amplification as described by Lejeune et al. and Menotti et al., respectively. Amplification of the small subunit rRNA gene was performed using the forward primer, Eb1, (5' CGACAGCCTGTGTG TGAGAATAC 3') and the species-specific reverse, Eb5, (5' CAACGAATGACTTGACCCTGGTAA 3')

for the diagnosis of *E. bienewisi* [11]. The primer sets FEI1 (5' GCAAGGGAGGAATGGAACAGAACAG 3') and REI1 (5' CACGTTTCAGAACCCATT ACACAGC 3') amplified a 127 bp fragment specific for *E. intestinalis* [12]. The PCR reaction mixture consisted of 10 µl of 2x Master Mix RED (Ampliqon, Copenhagen, Denmark), which consisted of 1.5 mM MgCl₂, 10 pmol of each primer, and 20 ng of DNA template in a final volume of 20 µl. Distilled water was used as the negative control.

DNA was amplified using a PCR machine (Analytik, Jena, Germany) under the following condition: 10 min at 94 °C, followed by 35 cycles of 30s at 94 °C, 20s at 61.5°C, 30s at 72 °C, and a final extension at 72°C for 10 min. The PCR products were separated on 2% agarose (Takara Shuzo, Kyoto, Japan).

The gels were stained with ethidium bromide (0.1 mg/ml) and visualized using UV transilluminator (UVItec, Cambridge, UK). The bands of 127 bp and 180 bp showed infection with *E. bienewisi* and *E. intestinalis*, respectively. The PCR products were separated on 2% agarose gel (Takara Shuzo, Kyoto, Japan) in 0.5x Trisborate-EDTA buffer, stained with ethidium bromide (0.1 mg/ml), and visualized under UV light (UVItec, Cambridge, UK).

CD4⁺ T cell count

Peripheral blood of HIV-positive patients was collected into EDTA tubes and 20 µl of it was stained with a fluorescent anti-CD4 monoclonal antibody. The CD4⁺ T cell whole count was performed by a flow cytometer.

Data analysis

To analyze the data, Chi-square test, Pearson correlation coefficient, Fisher's exact test, and logistic regression were run in SPSS, version 21.

Results

The overall frequency of *Microsporidia* spp. infection among the participants as detected by microscopy (modified trichrome stain; Figure 1) and




Figure 1. Modified trichrome staining of *Enterocytozoon bienewisi* spores isolated from the stool samples; 1000x magnification




Figure 2. Agarose gel electrophoresis (2%) of random PCR products (127 bp). Lane 1: negative control; lane 2: positive control; lane 3: PCR products of positive samples; lane M: 100-bp DNA ladder

DNA-based PCR amplification was 10.5% (20/199). Microscopy and PCR yielded identical results (PCR was selected as the gold standard test), and all the DNAs extracted from positive isolates detected using Ryan trichrome stain were amplified well. *E. bienersi* was the only species in *Microsporidia* genus that was identified. In this study, the use of specific primers on the 18S rRNA locus of *E. bienersi* resulted in 127-bp PCR products (Figure 2); whereas no band of 180 bp was observed using the specific primers of *E. intestinalis*. Using the specific primers and the PCR method, 1/68 (1.47%), 10/72 (13.88%), and 9/59 (15.28%) of the immunocompetent controls, HIV-positive, and cancer-positive patients were infected with *E. bienersi*, respectively.

The results showed that the prevalence of *E. bienersi* was significantly different in the immunodeficient and immunocompetent patients based

on their immune state and it was higher in the former group ($P=0.002$, CI 95%: 1.49-86.85; OR=11.37). Although there was no significant difference in the prevalence of *Microsporidia* infection among patients with different cancer types ($P>0.05$), it was more frequent among patients with leukemia (25%) followed by gastrointestinal cancer (22.2%). In addition, in HIV-positive patients, no significant difference was noted in terms of CD4⁺ cells count level and microsporidiosis frequency ($P>0.05$). Nonetheless, half of the HIV-positive cases (5/10) who were infected with *Microsporidia* had TCD4⁺ cell count < 200 μ l.

The highest and lowest prevalence rates of *Microsporidia* infection were respectively observed in the 40-49 (7, 13.5%) and 1-9 (1, 9.1%) and 20-29 (1, 3.8%) age groups. However, no significant differences were found among different age groups with respect to *Microsporidia* infection rate ($P<0.05$; Table 1).

Overall, the risk of *Microsporidia* morbidity among patients with diarrhea was 5.99 times higher than those without diarrhea and it was 5.18 times greater in cases with abdominal pain than the asymptomatic individuals ($P=0.002$ and $P=0.007$, respectively). In addition, the rate of recurrence of *E. bienersi* infection was compared among the three groups based on their clinical symptoms, and it was found that the HIV-positive group was significantly different in this regard ($P=0.001$; Table 2).

The results showed that out of the 199 precipitants, 116 and 83 individuals were male and female, respectively. Out of the 116 males, *E. bienersi* was detected in 13 (11.2%) cases, while in the 83 females, 7 (8.4%) were infected with *E. bienersi*. The results indicated no significant differences between males and females in *Microsporidia* infection ($P>0.05$, CI 95%: 0.522-3.6; Table 3).

Table 1. The frequency of *E. bienersi* in the participants based on their immune status and age

Subjects	<i>E. bienersi</i>	N	Mean age (Year)	SD	SEM	P-value
Immunocompetent	Negative	67	33.57	17.16	2.10	0.287
	Positive	1	15	-	-	
Cancer-positive	Negative	50	41.06	20.30	2.47	0.326
	Positive	9	33.56	24.47	8.16	
HIV/AIDS-positive	Negative	62	39.838	9.72	1.23	0.84
	Positive	10	40.50	8.40	2.66	

SD: Standard deviation; SEM: Standard Error of Mean; Significant difference at $P<0.05$

Table 2. The frequency of *E. bienersi* in the participants based on their clinical symptoms

Clinical symptoms		Total	<i>E. bienersi</i>		OR	95% CI for OR	P-value
			Negative (%)	Positive (%)			
Diarrhea	Negative	95(100%)	92(96.8%)	3(3.2%)	1	(1.70 21.17)	0.002*
	Positive	104(100%)	87(83.7%)	17(16.3%)	5.99		
	Total	199(100%)	179(89.9%)	20(10.1%)			
Abdominal pain	Negative	105(100%)	101(96.2%)	4(3.8%)	1	(1.67 16.11)	0.002*
	Positive	94(100%)	78(83%)	16(17%)	5.18		
	Total	199(100%)	179(89.9%)	20(10.1%)			
Vomiting	Negative	123(100%)	112(91.1%)	11(8.9%)	1	(0.539 3.47)	0.509
	Positive	76(100%)	67(88.2%)	9(11.8%)	1.37		
	Total	199(100%)	179(89.9%)	20(10.1%)			

* Significant difference at $P<0.05$

Table 3. The frequency of *E.bieneusi* in the participants based on gender

Subjects	Sex	<i>E.bieneusi</i>		Total	P-value
		Negative N (%)	Positive N (%)		
Immunocompetent	Female	36(100)	0(0)	36(100)	0.471
	Male	31(96.9)	1(3.1)	32(100)	
	Total	67(98.5)	1(1.5)	68(100)	
Cancer-positive	Female	18(85.7)	3(14.3)	21(100)	0.999
	Male	32(84.2)	6(15.8)	38(100)	
	Total	50(84.7)	9(15.3)	59(100)	
HIV/AIDS-positive	Female	22(84.6)	4(15.4)	26(100)	0.998
	Male	40(87)	6(13)	46(100)	
	Total	62(86.1)	10(13.9)	72(100)	

Significant difference at $P < 0.05$

Discussion

Microsporidia are one of the known causes of opportunistic infections in humans, especially in immunodeficient individuals. The prevalence of this infection ranges between 0% and 50% worldwide [13]. Parallel to the growing number of immunodeficient patients and the recognition of the HIV virus, the prevalence of infectious diseases has been on an uprising trend in the past few decades [14, 15]. Cancer-positive patients, transplant recipients, and especially those with AIDS, are the most susceptible groups to microbial infections. Moreover, insufficient immune system response can affect parasite clearance in these subjects [15]. A limited number of studies has been conducted on the incidence of intestinal microsporidiosis in AIDS and cancer patients, as well as transplant recipients [16, 17].

In this study, the overall prevalence of *Microsporidia* spp. infection was 10.05%. It was detected in 14.5% of the immunocompromised patients (13.88% and 15.28% in the HIV-positive and cancer-positive subjects, respectively) and in 1.47% of the immunocompetent cases with diarrhea. It is worth mentioning that in HIV-positive patients, access to care programs may reduce the infection rate. In our study, although we found a relatively high prevalence of 13.88% in HIV-positive patients, they all had received the anti-retroviral drug. However, this rate was lower than the prevalence rates reported in some former studies. For example, Mirjalali et al. detected *E. bieneusi* in 30.86% of the Iranian HIV-positive subjects [6]. However, Agholi et al. found *E. bieneusi* in 2.24% of HIV-positive patients in Shiraz, Iran [18].

E. bieneusi was the single species that was recognized in our study. Several studies have also reported that *E. bieneusi* was the most common agent of gastroenteritis [6, 19]. In Peru, Bern et al. investigated intestinal *Microsporidia* infection rate in patients with AIDS. In their study, *E. bieneusi* was also identified as the only *Microsporidia* [20]. Mirjalali et al. detected *E. bieneusi* and *E. intestinalis* and demonstrated that *E. bieneusi* was the most important cause of gastroenteritis. Kazemi et al. performed a study to identify the prevalence of microsporidiosis in the southwest of Iran. They reported both *E. bieneusi* and *E. intestinalis* in the samples [19]. In contrast, in

a study in India, *E. intestinalis* was the most common cause of microsporidiosis in patients with diarrhea [21].

The results of our study indicated that the risk of *Microsporidia* morbidity among the patients with diarrhea was 5.99 times higher than those without this symptom and it was 5.18 times greater in those with abdominal pain than the asymptomatic individuals. Moreover, there was a significant difference between immunocompromised patients and healthy individuals in terms of prevalence of *Microsporidia*. The results of this study were consistent with those of some other studies. Several studies confirmed the association between microsporidiosis or other intestinal parasitic infections and gastrointestinal diseases in immunodeficient patients [22, 23]. Moreover, the results of Samie et al. revealed that *Microsporidia* infection rate was higher in patients with diarrhea than others [24], which is in line with the current findings. Coyle et al. identified an association between microsporidiosis and diarrhea. They concluded that *Microsporidia* contaminated 44% of HIV-positive patients with diarrhea [25]. Similarly, studies were performed in Africa to examine the prevalence and clinical manifestations of intestinal microsporidiosis in AIDS patients in comparison to healthy subjects [26, 27]. They reported that *E. bieneusi* was the most common species in symptomatic patients. Conversely, Lobo et al. did not report any significant differences among immunocompromised subjects in *Microsporidia* infection rate based on clinical symptoms [28]. Further, in our study, the incidence of microsporidiosis in HIV-positive group did not significantly increase with declining CD4⁺ T cell count level.

The reports on the incidence of microsporidiosis in cancer-positive patients are insufficient [28]. It seems that those taking immunosuppressive drugs are more susceptible to infection presumably because their immune response is affected by these drugs [19]. We found that the prevalence of *E. bieneusi* was significantly different based on patients' immune state. The incidence of microsporidiosis in immunocompromised patients was significantly higher than immunocompetent individuals. In our study, the prevalence of *E. bieneusi* in cancer-positive cases was 15.28%. However, there was no significant difference

in the frequency of microsporidiosis among the subjects with different cancer types. Nonetheless, the incidence of the disease was higher in patients with leukemia and gastrointestinal cancer than others. Angela et al. also detected *Microsporidia* infection in 68/217 (31.33%) cancer-positive patients and only 5/144 (3.47%) healthy cases. The difference between the two groups was significant [29]. Kezemi et al. presented that cancer-positive patients were more at risk for microsporidiosis. They detected *Microsporidia* in 18% of these cases [19]. In our study, there was no significant difference in microsporidiosis rate between males and females. This finding was consistent with the results of studies performed in Malaysia and India. The authors also reported that even though the number of women who were positive for microsporidiosis was higher than men, the difference was not statistically significant [21]. On the contrary, in a study carried out by Tabatabaei in Iran, the infection rate was significantly higher in men than in women [30].

In addition, it should be mentioned that various factors such as the type of diagnostic method, the distribution of different individuals in the studied groups, and the diversity of species or genotypes of parasites may affect the results. One of the important factors is the type of laboratory methods used to identify the microorganism. There are several tests available to identify intestinal parasitic infections. Microscopy is the conventional diagnostic tool in parasitology laboratories; however, it has low sensitivity and specificity due to the following reasons. First, it is highly dependent on the operator's expertise. Diagnosis of small microorganisms or their forms such as microsporidian spores is very difficult using microscopic examination. In addition, degenerated or atypical spores may not be detected easily in the specimens. These factors compromise the sensitivity of the microscopy method. Second, the detection of *Microsporidia* species based on shape is usually difficult or impossible in direct examination, hence small spores must be observed in stained smears [31]. Third, the conventional examinations are not often used for the discrimination of these parasites; therefore, requesting specific diagnostic tests is necessary [32].

In recent years, researchers have focused on improving the diagnostic methods at the species/genotype level [33-35]. Various diagnostic assays, including PCR, have become available for the identification of parasites or fungi. Conventional PCR has been compared to microscopic examination for the identification of several microorganisms in clinical specimens [36]. This study compared conventional microscopy and PCR detection methods for the detection of *Microsporidia*. PCR is considered the gold standard as it has the highest sensitivity and specificity in identifying parasites. In this study, the results of microscopy and PCR were identical. However, DNA-based techniques do not require integration microorganisms; thus, the assays enable monitoring

any parasite DNA load in feces. Consequently, molecular-based protocols can be a good alternative to traditional methods in most laboratories, especially in a large scale. Nevertheless, there are some problems with using PCR-based methods in Iran. First, the method are not readily available, and second, the costs of performing these tests are higher than the other routine parasitology tests. In addition, PCR assay is unable to discriminate between the present and chronic forms of the disease.

Conclusion

As of yet, the prevalence rate of microsporidiosis has not been fully recognized in cancer-positive patients in Iran. However, there are a few studies on the prevalence rate of this infection among AIDS patients. In this study, we evaluated the prevalence of an important opportunistic parasite/fungal species, that is *Microsporidia*, in both immunocompromised (AIDS- and cancer-positive patients) and immunocompetent individuals. Since understanding the actual status and epidemiology of a parasite is important for decision-making, planning, and control strategies, we suggest the routine implementation of at least one of the procedures of PCR, ELISA, and/or staining method for the detection of *Microsporidia* spp. in immunocompromised patients in the reference laboratories, academic centers, or children's hospitals. Overall, we conclude that modified trichrome staining method is the suitable technique for the detection of *Microsporidia* spp. in most laboratories.

Acknowledgments

We wish to thank Dr Shahram Solaymani-Mohammadi who provided us insight and expertise that critically assisted the research. We also thank Mr Soltani who provided the specimens in Clinic of Behavioral Diseases. This work was supported by a grant from the Deputy of Research and Technology of Kerman University of Medical Sciences (Grant No. 94/449). We also appreciate the participants for their cooperation.

Author's contribution

Z. B. and S. S. M. contributed with the study conception, planned the experiments, and supervised the project. M. N. carried out the experiments. All the authors discussed the results and contributed to the final manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

Financial disclosure

This study was financially supported by the Deputy of Research of Kerman University of Medical Sciences.

References

1. Ghoyouchi R, Ahmadpour E, Spotin A, Mahami-Oskouei M, Rezamand A, Aminisani N, et al. *Microsporidiosis* in

- Iran: a systematic review and meta-analysis. *Asian Pac J Trop Med.* 2017; 10(4):341-50.
2. Ghamiloui M, Valadkhani Z, Rahimi F. A study of *microsporidiosis* in corneal scrapings of keratitis patients referring to Farabi Eye Hospital, Tehran, Iran in 2013-14. *Curr Med Mycol.* 2015; 1(3):39-44.
 3. Keeling PJ, Luker MA, Palmer JD. Evidence from beta-tubulin phylogeny that *microsporidia* evolved from within the fungi. *Mol Biol Evol.* 2000; 17(1):23-31.
 4. Zainudin N, Nasarudin SN, Periyasamy P, Mokhtar N, Noordin R, Osman E. Diagnosis of disseminated *microsporidiosis*: detection of circulating *Enterocytozoon bienewisi* DNA in blood of HIV/AIDS patients. *Trop Biom.* 2016; 33(4):761-70.
 5. Sak B, Kváč M, Kučerová Z, Květoňová D, Saková K. Latent *microsporidial* infection in immunocompetent individuals—a longitudinal study. *PLoS Negl Trop Dis.* 2011; 5(5):e1162.
 6. Mirjalali H, Mohebbali M, Mirhendi H, Gholami R, Keshavarz H, Meamar AR, et al. Emerging intestinal *microsporidia* infection in HIV+/AIDS patients in Iran: microscopic and molecular detection. *Iran J Parasitol.* 2014; 9(2):149-54.
 7. Waywa D, Kongkriengdaj S, Chaidatch S, Tiengrim S, Kowadisaburana B, Chaikachonpat S, et al. *Protozoan* enteric infection in AIDS related diarrhea in Thailand. *Southeast Asian J Trop Med Public Health.* 2001; 32(Suppl 2):151-5.
 8. Sulzyc-Bielicka V, Kotodziejczyk L, Jaczewska S, Bielicki D, Kładny J, Safranow K. Prevalence of *Cryptosporidium* sp. in patients with colorectal cancer. *Pol Przegl Chir.* 2012; 84(7):348-51.
 9. Saigal K, Khurana S, Sharma A, Sehgal R, Malla N. Comparison of staining techniques and multiplex nested PCR for diagnosis of intestinal microsporidiosis. *Diagn Microb Infect Dis.* 2013; 77(3):248-9.
 10. Garcia LS. *Diagnostic medical parasitology.* 4th ed. New York: American Society for Microbiology Press; 2001.
 11. Espern A, Morio F, Miegerville M, Illa H, Abdoulaye M, Meyssonier V, et al. Molecular study of *microsporidiosis* due to *E. bienewisi* and *E. intestinalis* among HIV-infected patients from two geographical areas: Niamey (Niger) and Hanoi (Vietnam). *J Clin Microbiol.* 2007; 18:1-15.
 12. Menotti J, Cassinat B, Porcher R, Sarfati C, Derouin F, Molina JM. Development of a real-time polymerase-chain-reaction assay for quantitative detection of *Enterocytozoon bienewisi* DNA in stool specimens from immunocompromised patients with intestinal *microsporidiosis*. *J Infect Dis.* 2003; 187(9):1469-74.
 13. Didier ES, Stovall ME, Green LC, Brindley PJ, Sestak K, Didier PJ. Epidemiology of *microsporidiosis*: sources and modes of transmission. *Vet Parasitol.* 2004; 126(1):145-66.
 14. Genta RM, Miles P, Fields K. Opportunistic *strongyloides* *stercoralis* infection in lymphoma patients. Report of a case and review of the literature. *Cancer.* 1989; 63(7):1407-11.
 15. Arbo A, Santos JI. Diarrheal diseases in the immunocompromised host. *Pediatr Infect Dis J.* 1987; 6(10):894-906.
 16. Galván A, Sánchez AM, Valentín MP, Henriques-Gil N, Izquierdo F, Fenoy S, et al. First cases of *microsporidiosis* in transplant recipients in Spain and review of the literature. *J Clin Microbiol.* 2011; 49(4):1301-6.
 17. Lono AR, Kumar S, Chye TT. Incidence of *microsporidia* in cancer patients. *J Gastrointest Cancer.* 2008; 39(1-4):124-9.
 18. Agholi M, Hatam GR, Motazedian MH. HIV/AIDS-associated opportunistic *protozoal* diarrhea. *AIDS Res Hum Retroviruses.* 2013; 29(1):35-41.
 19. Kazemi E, Tavalla M, Maraghi S, Yad MJ, Latifi M. Frequency of microsporidial infection in immunocompromised patients with staining and molecular methods based on internal transcribed spacer region gene in two cities of southwest Iran during 2013-2014. *Asian J Pharm Res Health Care.* 2016; 9(1):7-16.
 20. Bern C, Kawai V, Vargas D, Rabke-Verani J, Williamson J, Chavez-Valdez R, et al. The epidemiology of intestinal *microsporidiosis* in patients with HIV/AIDS in Lima, Peru. *J Infect Dis.* 2005; 191(10):1658-64.
 21. Saigal K, Sharma A, Sehgal R, Sharma P, Malla N, Khurana S. Intestinal *microsporidiosis* in India: a two year study. *Parasitol Int.* 2013; 62(1):53-6.
 22. Wumba R, Longo-Mbenza B, Menotti J, Mandina M, Kintoki F, Situakibanza NH, et al. Epidemiology, clinical, immune, and molecular profiles of *microsporidiosis* and *cryptosporidiosis* among HIV/AIDS patients. *Int J Gen Med.* 2012; 5:603-11.
 23. Assefa S, Erko B, Medhin G, Assefa Z, Shimelis T. *Intestinal parasitic* infections in relation to HIV/AIDS status, diarrhea and CD4 T-cell count. *BMC Infect Dis.* 2009; 9(1):155.
 24. Samie A, Obi CL, Tzipori S, Weiss L, Guerrant RL. *Microsporidiosis* in South Africa: PCR detection in stool samples of HIV-positive and HIV-negative individuals and school children in Vhembe district, Limpopo Province. *Trans R Soc Trop Med and Hyg.* 2007; 101(6):547-54.
 25. Coyle CM, Wittner M, Kotler DP, Noyer C, Orenstein JM, Tanowitz HB, et al. Prevalence of *microsporidiosis* due to *Enterocytozoon bienewisi* and *Encephalitozoon* (Septata) *intestinalis* among patients with AIDS-related diarrhea: determination by polymerase chain reaction to the *microsporidian* small-subunit rRNA gene. *Clin Infect Dis.* 1996; 23(5):1002-6.
 26. Endeshaw T, Kebede A, Verweij JJ, Zewide A, Tsige K, Abraham Y, et al. Intestinal *microsporidiosis* in diarrheal patients infected with human immunodeficiency virus-1 in Addis Ababa, Ethiopia. *Japanese J Infect Dis.* 2006; 59(5):306-10.
 27. Ojuromi OT, Izquierdo F, Fenoy S, Fagbenro-Beyioku A, Oyibo W, Akanmu A, et al. Identification and characterization of *microsporidia* from fecal samples of HIV-positive patients from Lagos, Nigeria. *PLoS One.* 2012; 7(4):e35239.
 28. Lobo ML, Xiao L, Antunes F, Matos O. *Microsporidia* as emerging pathogens and the implication for public health: a 10-year study on HIV-positive and-negative patients. *Int J Parasitol.* 2012; 42(2):197-205.
 29. Angela R, Suresh K. *Microsporidia* in stool from cancer patients. *J Med Sci.* 2007; 1(2):88-90.
 30. Tabatabaie F, Tafreshi ZA, Shahmohammad N, Pirestani M. Molecular detection of *microsporidiosis* in various samples of Iranian immunocompromised patients. *J Parasitic Dis.* 2015; 39(4):634-8.
 31. Ungar BL. Enzyme-linked immunoassay for detection of *Cryptosporidium* antigens in fecal specimens. *J Clin Microbiol.* 1990; 28(11):2491-5.
 32. Omoruyi BE, Nwodo UU, Udem CS, Okonkwo FO. Comparative diagnostic techniques for *Cryptosporidium* infection. *Molecules.* 2014; 19(2):2674-83.
 33. Ryan U, Cacciò SM. *Zoonotic* potential of Giardia. *Int J Parasitol.* 2013; 43(12):943-56.
 34. Ghoshal U, Dey A, Ranjan P, Khanduja S, Agarwal V, Ghoshal UC. Identification of opportunistic enteric parasites among immunocompetent patients with diarrhoea from Northern India and genetic characterisation of *Cryptosporidium* and *Microsporidia*. *Indian J Med Microbiol.* 2016; 34(1):60-6.
 35. Laude A, Valot S, Desoubreaux G, Argy N, Nourrisson C,

Pomares C, et al. Is real-time PCR-based diagnosis similar in performance to routine parasitological examination for the identification of *Giardia intestinalis*, *Cryptosporidium parvum*/*Cryptosporidium hominis* and *Entamoeba histolytica* from stool samples? Evaluation of a new commercial

multiplex PCR assay and literature review. Clin Microbiol Infect. 2016; 22(2):190.e8.

36. Elgun G, Koltas IS. Investigation of *Cryptosporidium* spp. antigen by ELISA method in stool specimens obtained from patients with diarrhea. Parasitol Res. 2011; 108(2):395-7.